Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...
Eli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected. Meanwhile, a notable ...
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy and hold for 20 years. On January 20, 2026, Guggenheim reduced its price target on Eli Lilly and Company (NYSE:LLY) from $1,163 to $1, ...
Zacks Investment Research on MSN
Eli Lilly (LLY) stock sinks as market gains: What you should know
In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change ...
Having stabilized following a severe downturn last summer, Viking Therapeutics has announced the completion of patient enrollment for a key clinical trial. This technical achievement marks a ...
Eli Lilly’s presence in France has spanned more than six decades, but rumors of an acquisition suggest the pharmaceutical giant could be looking to expand its footprint in the country.
Eli Lilly preparing €15 billion acquisition offer for French biotech Abivax, awaiting French Finance Ministry guidance Tirzepatide generated $24.8 billion revenue in first nine months of 2025, ...
Abivax shares surged in Paris after French media flagged possible Eli Lilly takeover talks. Reported €15 billion offer would nearly double Abivax’s market value. Analysts caution deal speculation ...
Shares of Eli Lilly & Co. LLY slipped 1.99% to $1,063.56 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.65% to 6,966.28 and ...
Jan 9 (Reuters) - Schrodinger (SDGR.O), opens new tab said on Friday it is collaborating with Eli Lilly (LLY.N), opens new tab to offer the pharmaceutical major's AI-based platform, TuneLab, on its ...
The acquisition is part of Celltrion's strategy to strengthen its competitiveness and establish a production base within the United States. Celltrion plans to invest up to $482 million in its new ...
On the Jan. 5, 2026, episode of The Morning Filter podcast, Morningstar Chief US Market Strategist Dave Sekera commented on what the Food and Drug Administration’s approval of Novo Nordisk’s NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results